Latest Press Releases

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

MILAN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration ...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China

PR Newswire YANTAI, China, Aug. 13, 2025 YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met ...

Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030

PR Newswire BOSTON, Aug. 13, 2025 "Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the ...

COLGATE DENTAL VEER ANTHEM LAUNCHED TO EMPOWER KIDS TO BE THEIR OWN HEROES OF ORAL HEALTH

PR Newswire MUMBAI, India, Aug. 13, 2025 Released close to Independence Day, the anthem is penned by lyricist Swanand Kirkire and composed by Micu Patel Link to the anthem - Colgate Dental Veer Anthem MUMBAI, India, Aug. 13, 2025 ...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

PR Newswire HONG KONG, Aug. 12, 2025 - The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. - ASC47 ...

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

PR Newswire NEW YORK, Aug. 12, 2025 NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Gait analysis and pain measures show that subtly adjusting the angle of the foot during walking may reduce knee pain caused by osteoarthritis. This approach may also ...

MindHYVE.ai Partners with ICS Pakistan and NEI Pakistan to Revolutionize Nursing Education with AI-Powered ArthurAI

PR Newswire ISLAMABAD, Aug. 12, 2025 ISLAMABAD, Aug. 12, 2025 /PRNewswire/ --In a pioneering step towards elevating nursing education in Pakistan, MindHYVE.ai has signed strategic Memorandum of Understanding (MoU) with the Institute of ...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

PR Newswire LAS VEGAS, Aug. 12, 2025 Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, Biosyngen, KSQ ...

Children's Hospital of Philadelphia, Clinic for Special Children Discover Ultra Rare Form of Neuroinflammatory Disease is Much More Common in Old Order Amish than General Population

PR Newswire PHILADELPHIA and GORDONVILLE, Pa., Aug. 12, 2025 By working closely with the Amish community, clinicians are able to gather the critical information to effectively treat patients with a genetic neuroinflammatory condition ...

Post-Hoc FUEL Trial Analysis Shows Udenafil Significantly Improves Exercise Capacity in Fontan Patients with Reduced Baseline Function

PR Newswire SEOUL, South Korea, Aug. 12, 2025 SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 ...

pH-D Feminine Health Launches First FDA-Cleared Phase 3 Clinical Trial for Boric Acid Suppositories

PR Newswire NASHVILLE, Tenn., Aug. 12, 2025 NASHVILLE, Tenn., Aug. 12, 2025 /PRNewswire/ -- pH-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed ...

IBS in America: Despite advances, IBS remains a burden for many millions

PR Newswire BETHESDA, Md., Aug. 12, 2025 A new AGA-sponsored survey conducted by The Harris Poll, a Stagwell (STGW) agency, reveals that IBS symptoms disrupt patients' productivity and personal activities 19 days each month, impacting both ...

Start the school year strong with healthy sleep habits

PR Newswire DARIEN, Ill., Aug. 12, 2025 Student Sleep Health Week highlights the powerful connection between sleep and well-being DARIEN, Ill., Aug. 12, 2025 /PRNewswire/ -- As families prepare for another exciting school year, there's ...

ViCentra to Bring Smartphone-Based Closed Loop Therapy to People with Diabetes in Early 2026

PR Newswire UTRECHT, the Netherlands, Aug. 12, 2025 Kaleido patch pump system with Diabeloop's DBLG2 algorithm and Dexcom G7 CGM to launch in Germany and the Netherlands in early 2026, bringing smartphone-controlled closed loop therapy to ...

MNA: Nurses Share Report by DPH/CMS Finding Tenet/St. Vincent Hospital Administration Placed All Patients in Immediate Jeopardy of Serious Harm Resulting in at Least Three Patient Deaths and Other Complications

PR Newswire WORCESTER, Mass., Aug. 11, 2025 Report threatened Tenet/SVH with its most severe sanction – termination of any funding for the care of patients under Medicare and Medicaid, calling for corrective action plan to restore safety ...

New Class, New Conversations: What Incoming Freshmen Want Colleges to Know

PR Newswire FORT WORTH, Texas, Aug. 11, 2025 TimelyCare Report: 65% of Students Have Already Been to Therapy Before Starting College, 83% Expect Campus Mental Health Support FORT WORTH, Texas, Aug. 11, 2025 /PRNewswire/ -- Belonging, ...

Global Telemedicine Market to Grow at 11.3% CAGR Through 2030

PR Newswire BOSTON, Aug. 11, 2025 "Regional Adoption, Expanding Applications, and Emerging Opportunities Drive Growth in Telemedicine—From Telepsychiatry to IT-Enabled Healthcare Platforms" BOSTON, Aug. 11, 2025 /PRNewswire/ -- According ...

Meridian Hospital: Healthy Women Package

Trusted Healthcare for Every Stage of Life!Meridian Hospital is a trusted name in quality healthcare, committed to delivering compassionate, patient-centred medical services. Known for its state-of-the-art infrastructure, advanced diagnostic ...

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

PR Newswire FRANKFURT, Germany, Aug. 8, 2025 Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. ...

A Novel Technique Using 3D Printing to Increase Precision in Oral Surgeries

PR Newswire GLEN ALLEN, Va., Aug. 8, 2025 Researchers from Yonsei University and Seoul National University have developed a customizable 3D-printed polycaprolactone (PCL) mesh as a substitute for traditional collagen membranes in guided bone ...

Memorial Hermann Health System Introduces Noninvasive Ultrasound Technology in Treatment of Liver Tumors

PR Newswire HOUSTON, Aug. 8, 2025 HOUSTON, Aug. 8, 2025 /PRNewswire/ -- Memorial Hermann-Texas Medical Center announced today that it will begin using a new FDA-approved ultrasound device to perform targeted, non-invasive treatment of liver ...

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

PR Newswire YANTAI, China, Aug. 8, 2025 YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical ...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

PR Newswire EAST HANOVER, N.J., Aug. 11, 2025 Ad hoc announcement pursuant to Art. 53 LR EAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab ...

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

PR Newswire HONG KONG, Aug. 10, 2025 HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study ...

Dr. Thomas Pane Answers a Common Question: Do I Need a Tummy Tuck or Just Liposuction?

PR Newswire NORTH PALM BEACH, Fla., Aug. 9, 2025 In a recent video Q&A, board-certified plastic surgeon Dr. Pane breaks down the differences between tummy tuck, revision surgery, and liposuction, helping patients choose the right path after ...

US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

PR Newswire TAIPEI and SAN DIEGO, Aug. 7, 2025 TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and ...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

PR Newswire LAS VEGAS, Aug 6, 2025 The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and increased awareness about bladder ...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

PR Newswire LAS VEGAS, Aug 6, 2025 The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these therapies, and a surge in the number of CLK inhibitors ...

Start the School Year Right: Minnesota Dental Association Recommends Back-to-School Dental Visits

PR Newswire MINNEAPOLIS, Aug. 6, 2025 MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Tooth decay is the most common chronic disease in children and, if left untreated, may lead to infections and problems with focusing on school. The Minnesota ...

Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer

PR Newswire BRISBANE, Calif., Aug. 6, 2025 – Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones – – Final module for the first version of Freenome's colorectal cancer test has ...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

PR Newswire DUBLIN, Aug. 5, 2025 Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patients ...

Latest Press Releases

Premium Press Releases »

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

Press Releases »

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China

Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030

COLGATE DENTAL VEER ANTHEM LAUNCHED TO EMPOWER KIDS TO BE THEIR OWN HEROES OF ORAL HEALTH

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

MindHYVE.ai Partners with ICS Pakistan and NEI Pakistan to Revolutionize Nursing Education with AI-Powered ArthurAI

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Children's Hospital of Philadelphia, Clinic for Special Children Discover Ultra Rare Form of Neuroinflammatory Disease is Much More Common in Old Order Amish than General Population

Post-Hoc FUEL Trial Analysis Shows Udenafil Significantly Improves Exercise Capacity in Fontan Patients with Reduced Baseline Function

pH-D Feminine Health Launches First FDA-Cleared Phase 3 Clinical Trial for Boric Acid Suppositories

IBS in America: Despite advances, IBS remains a burden for many millions

Start the school year strong with healthy sleep habits

ViCentra to Bring Smartphone-Based Closed Loop Therapy to People with Diabetes in Early 2026

MNA: Nurses Share Report by DPH/CMS Finding Tenet/St. Vincent Hospital Administration Placed All Patients in Immediate Jeopardy of Serious Harm Resulting in at Least Three Patient Deaths and Other Complications

New Class, New Conversations: What Incoming Freshmen Want Colleges to Know

Global Telemedicine Market to Grow at 11.3% CAGR Through 2030

Meridian Hospital: Healthy Women Package

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

A Novel Technique Using 3D Printing to Increase Precision in Oral Surgeries

Memorial Hermann Health System Introduces Noninvasive Ultrasound Technology in Treatment of Liver Tumors

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

Dr. Thomas Pane Answers a Common Question: Do I Need a Tummy Tuck or Just Liposuction?

US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

Start the School Year Right: Minnesota Dental Association Recommends Back-to-School Dental Visits

Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma